What is New In Our Community
Get access to our breaking news, company information, publications, and resources
Press Releases
Pillar Biosciences to Present at NYBIO | NYSE Life Science Company Showcase on December 14th
Natick, MA – December 7, 2023 – Pillar Biosciences is pleased to announce that Randy Pritchard, Chief Executive Officer, and Vincent Ricci, Chief Financial Officer, will be presenting at the NYBIO | NYSE Life Science Company Showcase on December 14th. This event, organized by NewYorkBIO in partnership with the New York Stock Exchange (NYSE), brings together New York’s financial community and life science-focused companies to highlight innovative solutions and treatments that are revolutionizing patient care. The showcase will take place at the New York Stock Exchange, providing a platform for emerging biotech and life science companies to present their groundbreaking …
Pillar Biosciences to Present New Scientific Data at Association for Molecular Pathology Annual Meeting
NATICK, Mass. – November 8, 2023 – (PR NEWSWIRE) – Pillar Biosciences, Inc., the leader in Decision Medicine™, today announced the company and scientific collaborators …
Beckman Coulter Life Sciences and Pillar Biosciences Announce NGS Application Development Pipeline for the Biomek NGeniuS System
Assays Focus on Accelerating Cancer Research INDIANAPOLIS – November 6, 2023 – Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, continues …
Pillar Biosciences Launches oncoReveal Core LBx, an NGS Kit to Enable Localized Liquid Biopsy-Based Tumor Profiling
Research Use Only (RUO) NGS Kit will provide a simple, automatable, industry-leading liquid biopsy workflow NATICK, Mass. – September 19, 2023 – (PR NEWSWIRE) – …
Resources
Minimizing Sample Failure Rates for Challenging Clinical Tumor Samples
Learn moreQuality metrics for enhanced performance of an NGS panel using single-vial amplification technology
Learn moreExquisitely Platinum-Sensitive Triple-Negative Breast Cancer, Time for BRCA Methylation Testing?
Learn moreAbnormal TP53 Predicts Risk of Progression in Patients With Barrett’s Esophagus Regardless of a Diagnosis of Dysplasia
Learn moreLocalizing next-generation sequencing testing for cancer patients
Learn moreSept 30, 2021
Effective and Accurate CNV Calling Using the PiVAt Bioinformatics Platform
Learn More
Jan 05, 2019
Clinical significance of multiple gene detection with a 22-gene panel in formalin-fixed paraffin-embedded specimens of 207 colorectal cancer patients
Learn More
Aug 28, 2018
Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing
Learn More
Jul 12, 2017
Amplification of overlapping DNA amplicons in a single-tube multiplex PCR for targeted next-generation sequencing of BRCA1 and BRCA2
Learn More
Apr 06, 2017
Feasibility Study of Molecular Profiling of Gastric Cancer Specimens From Rwanda
Learn More
Pillar Biosciences Inc.
9 Strathmore Rd., Natick MA, 01760